Laddar...
SB8: A Bevacizumab Biosimilar
SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy vol...
Sparad:
| I publikationen: | Target Oncol |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer International Publishing
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7733936/ https://ncbi.nlm.nih.gov/pubmed/33206282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00776-0 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|